Tuesday, 27 September 2016
Rexahn Pharmaceuticals Inc.
|AMEX : RNN|
26 Sep 16 00:00
01:45 | 27/9/16
The Voice Registrar
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on September 12, 2016 announced that it has initiated stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients. more»
23:52 | 26/9/16
The stock of Rexahn Pharmaceuticals, Inc. (RNN) formed a down wedge with $0.19 target or 13.00% below today's $0.22 share price. more»
23:30 | 26/9/16
In the past trading session, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) highlighted upward shift of +0.2755% or +0.0006 points to $0.2184. more»
22:52 | 24/9/16
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) up 1.44% for the past 5 days, is under coverage of 2 analysts who collectively assign a buy rating on stock. more»
06:45 | 24/9/16
Curious Investors have been seeking information about shares of Rexahn Pharmaceuticals, Inc. (:RNN) after the stock moved -1.56%, hitting the $0.21 price point following a recent trade. more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW